Compare Genuine Parts Company (GPC) vs Revvity Inc (RVTY) Price & Performance

GPC trades at $133.47, down 0.8% today, with a bullish technical trend and strong institutional support. Recent Q2 2026 earnings beat estimates with EPS of $2.15 versus $2.08 expected, driven by 6% sales growth. The stock is near its 52-week high, supported by a consensus price target of $148.67, though net income margins remain thin at 0.13%.

Outlook is positive with analyst consensus leaning buy, but risks include compressed profitability and high P/E ratio. The dividend yield adds income appeal, yet margin pressures from inflation and competition warrant caution for growth-focused investors.

RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.

The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.